Currently out of the existing stock ratings of Geoff Meacham, 209 are a BUY (61.29%), 104 are a HOLD (30.5%), 28 are a SELL (8.21%).

Geoff Meacham

Work Performance Price Targets & Ratings Chart

Analyst Geoff Meacham, currently employed at BAML, carries an average stock price target met ratio of 65.17% that have a potential upside of 30.29% achieved within 237 days.

Geoff Meacham’s has documented 697 price targets and ratings displayed on 54 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on KNSA, Kiniksa Pharmaceuticals Ltd at 13-Mar-2025.

Wall Street Analyst Geoff Meacham

Analyst best performing recommendations are on BTAI (BIOXCEL THERAPEUTICS).
The best stock recommendation documented was for BTAI (BIOXCEL THERAPEUTICS) at 1/7/2025. The price target of $7 was fulfilled within 1 day with a profit of $0.54 (7.16%) receiving and performance score of 71.62.

Average potential price target upside

of $88.91 (19.26%) on REGN (REGENERON PHARMACEUTICALS).
of $107.39 (53.48%) on BTAI (BIOXCEL THERAPEUTICS).
of $46.36 (18.28%) on LLY (ELI LILLY AND COMPANY).

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BMY Bristol-Myers Squibb Company BTAI BioXcel Therapeutics CMPI Checkmate Pharmaceuticals CVAC CureVac NV GILD Gilead Sciences IIVI II-VI INCY yte INO Inovio Pharmaceuticals JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany MRNA Moderna PFE Pfizer REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals KNSA Kiniksa Pharmaceuticals Ltd PMVP Pmv Pharmaceuticals PTCT PTC Therapeutics SGEN Seagen ABBV AbbVie ARAV Aravive CELG Celgene KYMR Kymera Therapeutics NBIX Neurocrine Biosciences ABOS Acumen Pharmaceuticals UTHR United Therapeutics VAXX Vaxxinity XLRN Acceleron Pharma ALNY Alnylam Pharmaceuticals ACHN Achillion Pharmaceuticals BBIO BridgeBio Pharma CMRX Chimerix CRBU Caribou Biosciences CRSP Crispr Therapeutics AG GRPH Graphite Bio ICPT Intercept Pharmaceuticals IPSC Century Therapeutics MYOV Myovant Sciences Ltd OMER Omeros PRTA Prothena plc RPRX Royalty Pharma Plc RTRX Travere Therapeutics TYRA Tyra Biosciences IGMS IGM Biosciences RANI Rani Therapeutics Holdings VIR Vir Biotechnology LIAN LianBio ADR AMLX Amylyx Pharmaceuticals JANX Janux Therapeutics RNA Avidity Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hartaj Singh (OPPENHEIMER)